| Autor: |
Shiferaw MB; Bahir Dar Regional Health Research Laboratory Center, Bahir Dar, Ethiopia., Tulu KT; Department of Biomedical Science, School of Health and Hospital, Adama Science and Technology University, Asella, Ethiopia., Zegeye AM; North Shoa Zone Health Department, Debre Berhan, Ethiopia., Wubante AA; West Gojjam Zone Health Department, Finote Selam, Ethiopia. |
| Jazyk: |
angličtina |
| Zdroj: |
AIDS research and treatment [AIDS Res Treat] 2016; Vol. 2016, pp. 1985452. Date of Electronic Publication: 2016 Jul 14. |
| DOI: |
10.1155/2016/1985452 |
| Abstrakt: |
Liver disease has emerged as the most common non-AIDS-related cause of death in HIV patients. However, there is limited data regarding this condition including our setting in Ethiopia. Hence, liver enzyme abnormalities among highly active antiretroviral therapy (HAART) experienced and HAART naïve patients were assessed in this study. A total of 164 HAART experienced and 164 HAART naïve patients were studied. Blood specimen was collected to determine alanine aminotransferase (ALT) and aspartate aminotransferase (AST), CD4 count, and viral hepatitis. The prevalence of liver enzyme abnormality was 20.1% and 22.0% among HAART experienced and HAART naïve patients, respectively. The HAART experienced patients had higher mean ALT than HAART naïve patients (P = 0.002). Viral hepatitis (AOR = 6.02; 95% CI = 1.87-19.39), opportunistic infections (AOR = 2.91; 95% CI = 1.04-8.19), current CD4 count <200 cells/mm(3) (AOR = 2.16; 95% CI = 1.06-4.39), and male sex (AOR = 1.83; 95% CI = 1.001-3.33) were associated with elevated ALT and/or AST. In conclusion, liver enzyme abnormalities were high in both HAART experienced and HAART naïve HIV-1 infected patients. Hence, monitoring and management of liver enzyme abnormalities in HIV-1 infected patients are important in our setting. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
